Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Mirxes Holding Company Limited ( (HK:2629) ) just unveiled an announcement.
Mirxes Holding Company Limited has completed enrolment of more than 6,000 participants in its CADENCE CRC clinical study, the first and largest registrational trial in Southeast Asia evaluating a blood-based colorectal cancer screening test. The study spans diverse ethnic groups and uses colonoscopy as a reference standard to validate the performance of the company’s miRNA-powered blood test for early detection in average- and high-risk adults.
With enrolment finished, the trial moves into final lab analysis and data evaluation, with topline results expected in 2026, and prior studies have shown sensitivity above 80% and specificity around 90% for early-stage colorectal cancer. Mirxes plans to commercialise the test as a Laboratory Developed Test in Singapore and selected Southeast Asian markets by mid-2026, aiming to boost screening uptake and address a substantial unmet need among an eligible population exceeding 1.2 billion adults across Asia.
More about Mirxes Holding Company Limited
Mirxes Holding Company Limited is a biotechnology company focused on developing blood-based diagnostics for cancer screening, leveraging a proprietary miRNA-centric multi-omics platform and AI-driven algorithms. The group operates across Southeast Asia, using its laboratory infrastructure and clinical network to bring non-invasive cancer tests, such as colorectal cancer blood screening, to market in the region.
Average Trading Volume: 1,191,087
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$6.7B
For detailed information about 2629 stock, go to TipRanks’ Stock Analysis page.